Drugs / Ad26.RSV.preF-based vaccine
Ad26.RSV.preF-based vaccine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05101486 | Nov 2021 → Mar 2022 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT05083585 | Oct 2021 → Mar 2022 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT05071313 | Oct 2021 → Apr 2022 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 3 | NCT05070546 | Sep 2021 → Aug 2022 | respiratory syncytial virus infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.RSV.preF based vaccine | “The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for...” NCT05070546 ↗ |
| Known as | Ad26/protein preF RSV vaccine | “Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus...” PMID 39536455 ↗ Nov 2024 |
| Known as | Ad26/protein RSV preF vaccine | “BACKGROUND: Respiratory syncytial virus (RSV) causes a significant disease burden in adults with chronic comorbidities. Rates of severe RSV disease and death are as high, or...” PMID 39536455 ↗ Nov 2024 |
| Modality | Vaccine | “Ad26/protein preF RSV vaccine” PMID 39536455 ↗ Nov 2024 |
| Route | Intramuscular | “Participants will receive a single intramuscular (IM) injection of study vaccine on Day 1.” NCT05070546 ↗ |